title: Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism.
abstract: 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) converts inactive 11-keto derivatives to active glucocorticoids within tissues and may play a role in the metabolic syndrome (MS). We used an antisense oligonucleotide (ASO) to knock down 11β-HSD1 in livers of C57BL/6J mice consuming a Western-type diet (WTD). 11β-HSD1 ASO-treated mice consumed less food, so we compared them to ad libitum-fed mice and to food-matched mice receiving control ASO. Knockdown of 11β-HSD1 directly protected mice from WTD-induced steatosis and dyslipidemia by reducing synthesis and secretion of triglyceride (TG) and increasing hepatic fatty acid oxidation. These changes in hepatic and plasma lipids were not associated with reductions in genes involved in de novo lipogenesis. However, protein levels of both sterol regulatory element-binding protein (SREBP) 1 and fatty acid synthase were significantly reduced in mice treated with 11β-HSD1 ASO. There was no change in hepatic secretion of apolipoprotein (apo)B, indicating assembly and secretion of smaller apoB-containing lipoproteins by the liver in the 11β-HSD1-treated mice. Our results indicate that inhibition of 11β-HSD1 by ASO treatment of WTD-fed mice resulted in improved plasma and hepatic lipid levels, reduced lipogenesis by posttranslational regulation, and secretion of similar numbers of apoB-containing lipoproteins containing less TG per particle.
authors.affiliation: Department of Medicine, Columbia University, New York, NY, USA.
authors.forename: Guoping
authors.initials: G
authors.lastname: Li
authors.forename: Antonio
authors.initials: A
authors.lastname: Hernandez-Ono
authors.forename: Rosanne M
authors.initials: RM
authors.lastname: Crooke
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Graham
authors.forename: Henry N
authors.initials: HN
authors.lastname: Ginsberg
mesh_terms: D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D001055:Apolipoproteins B / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002478:Cells, Cultured; D002853:Chromatography, Liquid; D004041:Dietary Fats / Q000009:adverse effects; D050171:Dyslipidemias / Q000139:chemically induced / Q000517:prevention & control; D004435:Eating / Q000187:drug effects; D005234:Fatty Liver / Q000139:chemically induced / Q000517:prevention & control; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D015151:Immunoblotting; D050356:Lipid Metabolism / Q000187:drug effects; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D014280:Triglycerides / Q000378:metabolism
chemical_list: D001055:Apolipoproteins B; D004041:Dietary Fats; D008079:Lipoproteins, VLDL; D016376:Oligonucleotides, Antisense; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1